NCT05591170

Brief Summary

The aim of this interventional study is to assess the effect of the single high dose of vitamin D on its serum metabolites in elderly. The main questions it attempts to answer is:

  1. 1.what is the effect of a single, high, oral dose of vitamin D3 (120,000 IU) on serum 25(OH)D3, 25(OH)D2, 24,25(OH)2D3, 3-epi-25(OH)D3, 1,25(OH)2D3, 24,25(OH)2D3/25(OH)D3 ratio, and 25(OH)D3/3-epi-25(OH)D3 ratio concentration at baseline, 3 days and 7 days after administration, compared to control group.
  2. 2.what is the influence of percentage of fat tissue on serum metabolites of vitamin D and their changes after bolus dose, compared to control group.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
58

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Apr 2021

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2021

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2021

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

October 19, 2022

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 24, 2022

Completed
Last Updated

February 9, 2023

Status Verified

February 1, 2023

Enrollment Period

5 months

First QC Date

October 19, 2022

Last Update Submit

February 7, 2023

Conditions

Keywords

vitamin D25(OH)D325(OH)D23-epi-25(OH)D324,25(OH)2D31,25(OH)2D3

Outcome Measures

Primary Outcomes (1)

  • Changes of serum vitamin D metabolites after the administration of 120 000 IU cholecalciferol compared to control group.

    Changes of serum 25(OH)D3, 25(OH)D2, 24,25(OH)2D3, 3-epi-25(OH)D3, 1,25(OH)2D3, 24,25(OH)2D3/25(OH)D3 ratio, and 25(OH)D3/3-epi-25(OH)D3 ratio concentration at baseline, 3 days and 7 days after the intervention, compared to control group.

    Measurements at baseline, 3 days and 7 days after.

Secondary Outcomes (1)

  • Influence of percentage of fat tissue on serum concentration of metabolites of vitamin D and their changes after bolus dose.

    Dual-Energy X-Ray Absorptiometry (DXA) at baseline, measurements of vitamin D metabolites at baseline, 3 days and 7 days after.

Study Arms (2)

Study Group

EXPERIMENTAL

Participants received single, high, oral dose of vitamin D3 (120,000 IU), serum 25(OH)D3, 25(OH)D2, 24,25(OH)2D3, 3-epi-25(OH)D3, 1,25(OH)2D3, 24,25(OH)2D3/25(OH)D3 ratio, and 25(OH)D3/3-epi-25(OH)D3 ratio concentration (measured by LC-MS/MS) at baseline, 3 days and 7 days after bolus dose were measured. The percentage of fat tissue was determined using Dual-Energy X-Ray Absorptiometry (DXA).

Drug: Cholecalciferol 120 000 IU

Control Group

NO INTERVENTION

Serum 25(OH)D3, 25(OH)D2, 24,25(OH)2D3, 3-epi-25(OH)D3, 1,25(OH)2D3, 24,25(OH)2D3/25(OH)D3 ratio, and 25(OH)D3/3-epi-25(OH)D3 ratio concentration (measured by LC-MS/MS) were measured at baseline, 3 days and 7 days after. The percentage of fat tissue was determined using Dual-Energy X-Ray Absorptiometry (DXA).

Interventions

single, oral administration of high dose of vitamin D

Also known as: Solderol
Study Group

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • written, informed consent,
  • age ≥ 60 years-old,
  • admission to the hospital due to emergency reasons.

You may not qualify if:

  • hypercalcemia,
  • nephrolithiasis,
  • kidney insufficiency,
  • documented vitamin D3 metabolism disorders such as sarcoidosis, parathyroid disease or genetic defects,
  • vitamin D3 supplementation within 6 months prior to the hospitalisation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Endocrinology, Centre of Postgraduate Medical Education

Warsaw, 01-813, Poland

Location

Related Publications (3)

  • Ilahi M, Armas LA, Heaney RP. Pharmacokinetics of a single, large dose of cholecalciferol. Am J Clin Nutr. 2008 Mar;87(3):688-91. doi: 10.1093/ajcn/87.3.688.

    PMID: 18326608BACKGROUND
  • Saleh L, Tang J, Gawinecka J, Boesch L, Fraser WD, von Eckardstein A, Nowak A. Impact of a single oral dose of 100,000 IU vitamin D3 on profiles of serum 25(OH)D3 and its metabolites 24,25(OH)2D3, 3-epi-25(OH)D3, and 1,25(OH)2D3 in adults with vitamin D insufficiency. Clin Chem Lab Med. 2017 Oct 26;55(12):1912-1921. doi: 10.1515/cclm-2016-1129.

    PMID: 28328526BACKGROUND
  • Leszczynska D, Szatko A, Kowalski K, Raczkiewicz D, Ostrowska M, Misiorowski W, Zgliczynski W, Glinicki P. The Effect of a Single High Dose of Vitamin D on Serum Levels of Its Metabolites in the Elderly. Front Biosci (Landmark Ed). 2022 Oct 25;27(10):289. doi: 10.31083/j.fbl2710289.

MeSH Terms

Conditions

Vitamin D Deficiency

Condition Hierarchy (Ancestors)

AvitaminosisDeficiency DiseasesMalnutritionNutrition DisordersNutritional and Metabolic Diseases

Study Officials

  • Wojciech Zgliczyński, Prof.

    Department of Endocrinology, Centre of Postgraduate Medical Education

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

October 19, 2022

First Posted

October 24, 2022

Study Start

April 1, 2021

Primary Completion

August 31, 2021

Study Completion

August 31, 2021

Last Updated

February 9, 2023

Record last verified: 2023-02

Data Sharing

IPD Sharing
Will not share

Locations